Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings
Launched by JOHNS HOPKINS UNIVERSITY · Nov 21, 2023
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping young people who are at high risk for suicide. Researchers are comparing two different approaches to see which one works better in preventing suicidal thoughts and actions. One approach is called the Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), which helps individuals create a plan to stay safe and provides support after a crisis. The other approach is called Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI), which teaches young people skills to cope with crises and resolve personal issues that may lead to suicidal thoughts. The trial is taking place in three diverse urban areas: Philadelphia, Baltimore, and New York City.
To participate in this study, individuals aged 12 to 19 who have recently visited an emergency department for concerns related to suicide may be eligible. This includes those who have expressed serious thoughts of harming themselves. Participants should also have a cell phone for communication and be able to speak and understand English or Spanish. Throughout the study, participants will receive support and treatment tailored to their needs. Importantly, the findings from this trial will help shape future care for young people facing suicidal challenges in emergency settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute care visit for suicide-related concern or screen positive on a suicide risk screener (serious SI as indicated by a C-SSRS screening endorsing question two "Have you actually had any thoughts of killing yourself?" in past four weeks or SA in past four weeks);
- • Has a cell phone with ability to receive phone calls and text messages over the 12-month follow-up;
- • Ability to speak, understand, and read in English or Spanish
- Exclusion Criteria:
- • Significant cognitive or developmental delays that prevent understanding or using SPI or IPT-A SCI. Participants must be verbally fluent and have the ability to communicate verbally. This will, in part, be determined by notes in Epic and/or by asking one of the patient's parents/clinicians;
- • Altered mental status that precludes ability to provide informed assent or consent (acute psychosis, intoxication, or mania);
- • Unable to provide informed consent (adults); assent (minors); permission (parents/caregivers).
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Saint Petersburg, Florida, United States
Philadelphia, Pennsylvania, United States
Chapel Hill, North Carolina, United States
New York, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Holly C Wilcox, PhD
Principal Investigator
Johns Hopkins Bloomberg School of Public Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported